ABSTRACT. There is currently no reported staging system for type 2 diabetes mellitus. Here, I attempted to stage type 2 diabetes mellitus in order to help clinicians, patients, and other interested individuals to effectively evaluate patient conditions.
Stage 2: Diabetes with no complications. This group includes patients with a FPG level of ≥126 mg/dL (7.0 mM), 2-h PG level on OGTT of ≥200 mg/dL (11.1 mM), HbA1C level of ≥6.5%, classic symptoms of hyperglycemia, or a random PG level of ≥200 mg/dL (11.1 mM) (Reaven, 1988 ; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997; Genuth et al., 2003; American Diabetes Association, 2010) . These patients may or may not have insulin resistance or classic symptoms of hyperglycemia.
Signs of insulin resistance or conditions associated with insulin resistance include acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small for gestational age birth weight (Genuth et al., 2003) .
Stage 3: Diabetes with mild complications. This group includes patients with mild complications, including microalbuminuria and mild diabetic retinopathy (such as microaneurysms, mild hemorrhages) (Ciulla et al., 2003; Levey et al., 2003) . Patients may or may not have hyperglycemia or higher or normal levels of fasting and 2-h plasma insulin or proinsulin or C-peptide on OGTT (Chiasson et al., 2002; Nathan et al., 2007) .
Stage 4: Diabetes with absolute insulin deficiency. This group includes patients with hyperglycemia, and absolute insulin deficiency which is based on clinical and/or laboratory evidence. Patients may have mild to moderate complications [such as diabetic nephropathy without kidney failure or diabetic retinopathy without proliferative diabetic retinopathy (PDR)] (Ciulla et al., 2003; Fong et al., 2004; KDOQI, 2007) .
Laboratory evidence includes levels of fasting plasm insulin or proinsulin or C-peptide lower than the normal lower limit on laboratory's measurement method, or levels of 2-h plasma insulin or proinsulin or C-peptide during OGTT <5 times of patient's levels of fasting plasma insulin or proinsulin or C-peptide. In addition, the ratio of fasting glucose to insulin or proinsulin or C-peptide, or of 2-h PG to insulin or proinsulin or C-peptide on OGTT (Sacks et al., 2011 ) may be considered.
Clinical evidence: In order to achieve desired glycemic goals, the optimal treatment is insulin therapy.
Stage 5: Diabetes with serious complications. This group includes patients with serious complications including hyperglycemic crises, as well as microvascular and macrovascular complications. Patients may have hyperglycemia, as well as higher or lower or normal levels of fasting plasma insulin or proinsulin or C-peptide.
Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are the two most serious acute metabolic complications in diabetes. The diagnostic criteria for DKA include plasma glucose level of >250 mg/dL, arterial pH of <7.30, serum bicarbonate level of <18 mEq/L, and positivity for urine ketone and serum ketone. The diagnostic criteria for HHS include plasma glucose level of >600 mg/dL, arterial pH of >7.30, serum bicarbonate level of >18 mEq/L, effective serum osmolality of >320 mOsm/kg, and stupor/coma (Kim, 2007; Kitabchi et al., 2009) .
Microvascular complications include retinopathy (neovascularization and vitreous or preretinal hemorrhage), nephropathy, neuropathy (sensory, including history of foot lesions, and autonomic, including sexual dysfunction and gastroparesis), and cardiomyopathy, and macrovascular complications include coronary heart disease, cerebrovascular disease, proliferative diabetic retinopathy, peripheral arterial disease, amputation, and foot ulceration (Genuth et al., 2003; Sacks et al., 2011) .
A summary of the staging for type 2 diabetes is shown in Table 1 . 
